SEQUENCE LISTING

<110> GlaxoSmithKline LLC

<120> FURIN INHIBITORS

<130> B1539.70003WO00

<140> Not Yet Assigned
<141> Concurrently Herewith

<150> US 62/670,050
<151> 2018-05-11

<160> 3

<170> PatentIn version 3.5

<210> 1
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Modified by FAM

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> Modified by TAMRA

<400> 1

Gln Arg Val Arg Arg Ala Val Gly Ile Asp Lys
1 5 10

<210> 2
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Modified by decanoyl

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Modified by chloromethylketone

<400> 2

Arg Val Arg Lys
1

<210> 3
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Modified by GalNAc-T2

<220>
<221> MISC_FEATURE
<222> (22)..(22)
<223> Modified by GFP

<400> 3

Gly Gly Gly Gly Ser Asp Ser Thr Ala Arg Ile Arg Arg Asn Ala Lys
1   5   10   15

Gly Gly Gly Gly Gly Ser
            20

SEQUENCE LISTING

<110> GlaxoSmithKline LLC

<120> FURIN INHIBITORS

<130> B1539.70003WO00

<140> Not Yet Assigned
<141> Concurrently Herewith

<150> US 62/670,050
<151> 2018-05-11

<160> 3

<170> PatentIn version 3.5

<210> 1
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Modified by FAM

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> Modified by TAMRA

<400> 1

Gln Arg Val Arg Arg Ala Val Gly Ile Asp Lys
1 5 10

<210> 2
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Modified by decanoyl

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Modified by chloromethylketone

<400> 2

Arg Val Lys Arg
1

<210> 3
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic polypeptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Modified by GalNAc-T2

<220>
<221> MISC_FEATURE
<222> (22)..(22)
<223> Modified by GFP

<400> 3

Gly Gly Gly Gly Ser Asp Ser Thr Ala Arg Ile Arg Arg Asn Ala Lys
1   5   10   15

Gly Gly Gly Gly Gly Ser
            20